Sarepta therapeutics announces fourth quarter and full-year 2024 financial results and recent corporate developments

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2024. “2024 performance represented the fruition of our multi-year strategy to become a self-sustaining profitable biotech dedicated to improving the lives of patients with rare genetic disease. after obtaining a broad label for our gene therapy elevidys covering the vast majority of duchenn.
SRPT Ratings Summary
SRPT Quant Ranking